Browse the evidence

Promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.

Practitioners should be aware of safety concerns associated with certain GLP-1 receptor agonists.

Mendelian randomisation did not find evidence that genetically proxied GLP-1RA increased suicide attempts in a general population cohort.

There is no genetic evidence to support an association between GLP-1RA and increased suicide attempts, suggesting safety in this regard.

Artificial intelligence (AI) is a pivotal tool in drug discovery for developing next-generation anti-obesity therapeutics.

Practitioners should consider integrating AI tools in their drug discovery processes for obesity treatments.

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

Identifying molecular targets for inducing muscle remodeling could provide new approaches to treat metabolic syndrome.

Targeting specific molecular pathways may enhance treatment options for metabolic syndrome patients.

The supramolecular GLP-1 receptor agonist (PA-GLP1) formulation achieved sustained serum concentrations for at least 40 days in a rat model of type 2 diabetes.

This formulation may provide a long-lasting treatment option for diabetes management.

The findings support nephroprotective mechanisms of GLP-1RAs independent of body weight and glycemic control.

This indicates that GLP-1RAs may be beneficial for kidney health beyond their metabolic effects.

BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.

Understanding the development process can inform future drug design strategies.

There is a better understanding of biomolecules related to obesity, including gut hormones and fat utilization.

Practitioners should consider the role of biomolecules in obesity management.

Alternative PET tracers and novel techniques have improved understanding of human BAT physiology.

Emerging imaging techniques can enhance research and clinical understanding of BAT's role in health.

GLP-1 medicines may suppress tumorigenesis through various mechanisms.

Further research is needed to understand the mechanisms by which GLP-1 medicines may affect tumorigenesis.

The exact molecule(s) that ‘sense’ mechanical loading and translate that signal to a biochemical event leading to upregulation of MPS remains elusive.

Further research is needed to identify the molecules involved in sensing mechanical loading.

GPR75 is an attractive pharmacological target for the treatment of obesity and metabolic syndrome.

Targeting GPR75 may lead to more effective treatments for obesity and metabolic syndrome.

Gene targeting of GPR75 is more effective than current pharmacologic therapies without the known side effects.

Gene targeting may provide a safer and more effective alternative to current obesity treatments.

GPR75 and its ligand promote hypertension, inflammation, obesity, and insulin resistance.

Understanding the role of GPR75 can inform strategies to mitigate obesity-related health risks.

Carbon monoxide (CO) has potential therapeutic applications in obesity treatment.

Practitioners might explore CO-based therapies as innovative options for obesity management.

GLP-1 RAs slow both thoracic and abdominal aneurysm growth.

GLP-1 RAs may be beneficial in managing aneurysms in clinical settings.

Resmetirom is the first drug approved for MASLD, demonstrating histological efficacy in addressing both steatohepatitis and fibrosis.

Practitioners can consider resmetirom as a treatment option for MASLD.

The review discusses the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders.

Understanding the role of metabolic drugs in managing inflammatory comorbidities can enhance treatment strategies.

Metabolic drugs may be repurposed as direct anti-inflammatory agents.

Exploring the repurposing of metabolic drugs could lead to new anti-inflammatory therapies.

The optimized nanocomplex of semaglutide with protamine and zinc exhibited a particle size of 196.0 nm and a zeta potential of -45.7 mV.

The nanocomplex's size and charge may influence its delivery and efficacy.

The nanocomplexes showed markedly delayed release of semaglutide, with only 19% drug release over 7 days.

The delayed release may improve the effectiveness of semaglutide in clinical settings.

Key chemobiological mechanisms implicated in obesity include dysregulated leptin-ghrelin signaling, chronic low-grade inflammation, and altered adipokine profiles.

Understanding these mechanisms can help in developing targeted interventions for obesity.

Receptor activity-modifying proteins (RAMPs) are involved in the incidence of obesity and diabetes mellitus.

Understanding the role of RAMPs may help in developing targeted therapies for obesity and diabetes.